GlassScriptPhysician profile
Gilbert R Dominguez
NPI 1275601478
$12,580.27
in general payments reported to CMS, 2019-2025
72 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,616 · 2020: $1,516 · 2021: $1,868 · 2022: $1,663 · 2023: $1,830 · 2024: $2,242 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,842 · Education: $50.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,842.33 |
| Education | $50.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,451.14 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,409.07 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $773.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $732.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $630.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $571.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $525.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $506.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $476.72 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.59 | 2019-2023 | Trintellix |
| Arbor Pharmaceuticals, INC. | $237.60 | 2019-2022 | |
| Esperion Therapeutics, INC. | $235.53 | 2020-2025 | Nexletol |
| Allergan, INC. | $220.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $214.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.63 | 2022-2023 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.